Nanosphere is advancing health care with innovative diagnostic tools that empower clinicians to make faster, better-informed treatment decisions for their patients. More

Verigene Clinical Microbiology Tests

Nucleic acid-based detection of infectious disease agents in clinical microbiology diagnostics. Gold nanoparticle probe technology: multiplex detection of amplified and non-amplified infectious disease targets.

 

Verigene Cardiac Tests

Sed ut perspiciatis unde omnis iste natus error sit voluptatem accusantium doloremque laudantium, totam rem aperiam, eaque ipsa quae ab illo inventore veritatis et quasi architecto beatae vitae dicta sunt explicabo.

Verigene Human Genetic Tests

The detection of single nucleotide polymorphisms (SNPs) and similar DNA sequence variations plays an important role in the identification of individual’s who are at risk for having an inherited genetic disorder or are at risk for passing on a disorder to offspring.

Verigene Pharmacogenetic Tests

Pharmacogenetics: genetic variation with differing response to drugs. Gold nanoparticle probe technology enables multitarget detection of single nucleotide polymorphism (SNPs) and similar DNA sequence variations that alter an individual’s metabolism of specific drugs.

Verigene Instruments

International Distributors

Nanosphere at ASM 2013

 

Visit Nanosphere in the exhibit area at American Society for Microbiology (ASM) Annual Meeting. Please click here for meeting information.

Booth #809 | May 19 - 21 | Denver, CO

Nanosphere at Society of Hospital Medicine Annual Meeting

Visit Nanosphere in the exhibit area at Society of Hospital Medicine Annual Meeting. Please click here for meeting information.

Booth #714 | May 17 - 18 | National Harbor, MD

New Validation and Clinical Outcome Data From Several Studies on Nanosphere's Gram-Positive and Gram-Negative Blood Culture Tests to Be Presented at ASM 2013

NORTHBROOK, IL -- 05/16/13 -- Nanosphere, Inc. (NASDAQ: NSPH), a leader in the development and commercialization of advanced molecular diagnostics systems, today announced that new validation and outcome data for select Verigene® clinical microbiology tests will be presented at the 113th General Meeting of the American Society for Microbiology (ASM) being held in Denver, CO from May 18 to May 21.

Nanosphere Announces Distribution and Collaboration Agreement With Hitachi High-Technologies Corporation

NORTHBROOK, IL -- 05/13/13 -- Nanosphere, Inc. (NASDAQ: NSPH), a leader in the development and commercialization of advanced molecular diagnostics systems, announced today it has signed a distribution and collaboration agreement with Hitachi High-Technologies Corporation (Hitachi High-Tech). The agreement grants Hitachi High-Tech exclusive rights to market Nanosphere products in Japan. As well, the two companies intend to collaborate on assay and platform development.

Nanosphere at MAD ID

 

Visit Nanosphere in the exhibit area at MAD ID. Please click here for meeting information.

Booth #8 | May 9 - 11 | Orlando, FL

Nanosphere Obtains CE Mark for Gram-Negative Blood Culture Test

NORTHBROOK, IL -- (MARKETWIRE) -- 03/13/13 -- Nanosphere, Inc. (NASDAQ: NSPH), a leader in the development and commercialization of advanced molecular diagnostics systems, announced today it has obtained the CE IVD Mark under the European Directive on In Vitro Diagnostic Medical Devices for its Gram-Negative Blood Culture test (BC-GN) on the automated sample-to-result Verigene® System. 

Webinar: Optimizing Therapy for Bloodstream Infections with Rapid Molecular Testing

Nanosphere is excited to sponsor an online presentation titled "Optimizing Therapy for Bloodstream Infections with Rapid Molecular Testing." This webinar features an expert panel and a discussion on how your institution can potentially improve patient outcome, healthcare cost, and antimicrobial stewardship with rapid molecular diagnostics.

Please watch the archived presentation at www.bsiwebinar.com

 

Technical Support

For current customers only